Phase II trial of intermediate dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma

Cancer

Volumn 85, Issue 5, 1999, Pages 1145-1150

  Dodd, Paul M ^a,b   McCaffrey, John A ^a,b   Mazumdar, Madhu ^a   Scher, Howard ^a,b   Vlamis, Vaia ^a   Higgins, Geralyn ^a   Herr, Harry ^a,b   Bajorin, Dean F ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Chemotherapy; Cisplatin; Doxorubicin; Methotrexate; Transitional cell carcinoma; Urothelial tract; Vinblastine

Indexed keywords

CISPLATIN; DOXORUBICIN; METHOTREXATE; VINBLASTINE;

ADULT; AGED; ANEMIA; ARTICLE; BLADDER CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUROPATHY; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TREATMENT PLANNING; UROTHELIUM; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PATIENT SELECTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UROLOGIC NEOPLASMS; VINBLASTINE;

EID: 0032967614     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990301)85:5<1145::AID-CNCR19>3.0.CO;2-G     Document Type: Article

References (17)

1. Sternberg CN, Yagoda A, Scher HI, Watson RC, Geller N, Herr HW, et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Cancer 1989;64:2448-58.
2. Loehrer PJ Sr., Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992;10:1066-73.
3. Logothetis CJ, Dexeus FH, Finn L, Sella A, Amato RJ, Ayala A, et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990;8:1050-5.
4. Logothetis CJ, Dexeus FH, Sella A, Amato J, Kilbourn RG, Finn L, et al. Escalated therapy for refractory urothelial tumors: methotrexate-vinblastine-doxorubicin-cisplatin plus unglycosylated human granulocyte-macrophage colony-stimulating factor. J Natl Cancer Inst 1990;82:667-72.
5. Loehrer PJ Sr., Elson P, Dreicer R, Hahn R, Nichols CR, Williams R, et al. Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial. J Clin Oncol 1994;12:483-8.
6. Seidman AD, Scher HI, Gabrilove JL, Bajorin DF, Motzer RJ, O'Dell M, et al. Dose intensification of M-VAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer. J Clin Oncol 1993;11:408-14.
7. Sternberg CN, de Mulder PHM, van Oosterom AT, Fossa SD, Giannarelli D, Soedirman JR. Escalated M-VAC chemotherapy and recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) in patients with advanced urothelial tract tumors. Ann Oncol 1993;4: 403-7.
8. Moore MJ, Iscoe N, Tannock IF. A phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte-macrophage colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional cell carcinoma of the urothelium. J Urol 1993;150:1131-4.
9. Logothetis CJ, Finn LD, Smith T, Kilbourn RG, Ellerhorst JA, Zukiwski AA, et al. Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial. J Clin Oncol 1995;13:2272-7.
10. McCaffrey JA, Hilton S, Mazumdar M, Sadan S, Heineman M, Hirsch J, et al. Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional cell carcinoma. J Clin Oncol 1997;15:2449-55.
11. Turner AG. Methotrexate. In: Oliver RTD, Hendry WF, Bloom HJC, editors. Bladder cancer: principles of combination therapy. Kent: Butterworth, 1981:219-29.
12. Hall RR, Newling DW, Ramsden PD, Richards B, Robinson MR, Smith PH. Treatment of invasive bladder cancer by local resection and high dose methotrexate. Br J Urol 1984; 56:668-72.
13. Shapiro WR, Young DF, Mehta BM. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular, and lumbar injections. N Engl J Med 1975;293:161-6.
14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
15. Gardner MJ, Altman DG. Estimating with confidence. Br Med J 1988;296:1210-1.
16. Geller NL, Sternberg CN, Penenberg D, Scher H, Yagoda A. Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy. Cancer 1991;67: 1525-31.
17. Saxman SB, Propert KJ, Einhorn LH, Crawford DE, Tannock I, Raghavan D, et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1997;15:2564-9.